Should I Buy NUTX? NUTX 2026 Analysis

Should You Buy Nutex Health Inc (NUTX) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

99.900

1 Day change

-2.03%

52 Week Range

193.070

Analysis Updated At

2026/02/05

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Intellectia Proprietary Trading Signals
- AI Stock Picker: no signal on given stock today.
- SwingMax: No signal on given stock recently.
Not a good buy right now for an impatient buyer: the stock is in a sharp downside move (-19.5% today) with bearish momentum still expanding, and there’s no proprietary buy signal to justify stepping in aggressively.
If you must act immediately: this is a high-risk oversold bounce attempt near support, not a clean buy setup; the better stance based on the data is hold / wait for stabilization (reclaim of key levels) rather than buying into a falling move.
Event timing: earnings are coming 2026-02-18 (after hours), which can heavily move the stock; without a clear edge from signals/options/news, it’s not an attractive “buy now.”

Technical Analysis

Trend/Momentum: Bearish. MACD histogram -5.082 and negatively expanding indicates downside momentum is still strengthening.
Overbought/Oversold: RSI(6) 16.0 = deeply oversold, which can trigger short-term bounces, but does not by itself confirm a bottom.
Moving averages: Converging MAs suggest a transition zone, but the current price action (large drop) favors bears until price stabilizes.
Key levels:
- Support: S2 97.783 (nearby), then psychological ~100 area
- Resistance: S1 112.887 (first level to reclaim), Pivot 137.335, then R1 161.783
Pattern-based expectation (similar candlesticks): estimated odds favor a modest rebound profile (~0.6% next day, 1.71% next week, 7.2% next month), but this conflicts with the still-worsening MACD momentum—so any bounce is likely tactical, not trend-confirming.

Positive Catalysts

- Oversold condition (RSI ~16) increases the probability of a short-term relief bounce, especially near ~97.8–100 support.
- 2025/Q3 revenue growth was very strong (+239.87% YoY), which can support bullish narratives if earnings/reports confirm durability.
- Gross margin improved to 57.83% (up YoY), implying better unit economics.
- Upcoming earnings (2026-02-18) could act as a catalyst if results/forward commentary surprise positively.

Neutral/Negative Catalysts

- Severe selloff today (-19.5%) indicates active distribution and weak near-term sentiment.
- MACD bearish and expanding: suggests downside pressure is not done, making “catching the bottom” unattractive right now.
- Profitability trend flagged as weak YoY: Net income down -730.78% YoY and EPS down -551.16% YoY (even if still positive in absolute terms, the reported YoY deterioration is a sentiment drag).
- No news support in the last week and no proprietary buy signal (AI Stock Picker / SwingMax) to justify immediate entry.
- Macro tape is risk-off today (S&P 500 -1.07%), which can pressure smaller/more volatile names.

Financial Performance

Latest quarter: 2025/Q3
- Revenue: $267.804M, +239.87% YoY (strong top-line acceleration)
- Gross Margin: 57.83%, up YoY (improving margin profile)
- Net Income: $55.435M, down -730.78% YoY (sharp YoY decline as reported)
- EPS: 7.76, down -551.16% YoY (sharp YoY decline as reported)
Overall: strong revenue and margin expansion, but the reported YoY profitability decline undermines confidence and likely contributes to the heavy price pressure.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target change data was provided, so recent Wall Street revisions can’t be confirmed.
With the available info, the “pros vs cons” view skews mixed: Pros = explosive revenue growth and improved gross margin; Cons = reported YoY drop in net income/EPS and a breakdown in price momentum (suggesting the market is currently voting against the story).
Influential/political trading: No recent congress trading data available; hedge funds and insiders are reported as Neutral with no significant recent trend.

2 Analyst Rating

Wall Street analysts forecast NUTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NUTX is 265 USD with a low forecast of 230 USD and a high forecast of 300 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

0 Hold

0 Sell

Moderate Buy

Current: 101.970

Low

230

Averages

265

High

300

Current: 101.970

Low

230

Averages

265

High

300

Maxim

Buy

downgrade

$225 -> $205

AI Analysis

2025-08-26

Reason

Maxim

Price Target

$225 -> $205

AI Analysis

2025-08-26

downgrade

Buy

Reason

Maxim lowered the firm's price target on Nutex Health to $205 from $225 and keeps a Buy rating on the shares. On August 14th, the company filed an NT 10-Q notification of inability to timely file its 10-Q for the three months ended 6/30/25, due to the incorrect accounting classification of certain non-cash obligations, the analyst tells investors in a research note. The firm views the accounting restatements, arbitration dynamics, and lawsuits against Nutex's primary arbitration vendor, HaloMD, as potential headwinds to the stock price, Maxim added.

Maxim

Buy

maintain

$100 -> $225

2025-05-20

Reason

Maxim

Price Target

$100 -> $225

2025-05-20

maintain

Buy

Reason

NUTX Should I Buy

NUTX Should I Buy

Should You Buy Nutex Health Inc (NUTX) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch